Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose psilocybin for pain in fibromyalgia
NL-OMON55974Phase 2Not yet recruiting
- Sponsor
- Maastricht University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in fibromyalgia (FM) (3 arms), sponsored by Maastricht University. Primary endpoints: Pressure pain threshold, Cold pressor test and 2 more. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NL-OMON55974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55974.